Detalhe da pesquisa
1.
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Gynecol Oncol
; 178: 110-118, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839313
2.
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
Oncologist
; 27(12): 1048-1057, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36146944
3.
Metabolism and Disposition of [14C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors.
Drug Metab Dispos
; 50(7): 989-997, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35504658
4.
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Invest New Drugs
; 40(5): 1042-1050, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35932388
5.
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Invest New Drugs
; 39(2): 488-498, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33089874
6.
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Br J Cancer
; 123(11): 1590-1598, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32913286
7.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Blood
; 131(13): 1415-1424, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29348128
8.
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Invest New Drugs
; 37(1): 87-97, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29781056
9.
Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
Br J Clin Pharmacol
; 85(11): 2568-2579, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31355467
10.
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Br J Clin Pharmacol
; 85(7): 1464-1473, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30845347
11.
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Br J Haematol
; 169(4): 534-43, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25733005
12.
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
Target Oncol
; 17(1): 15-24, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34843044
13.
Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine.
J Hematol Oncol
; 15(1): 56, 2022 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545778
14.
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Clin Transl Sci
; 14(3): 1069-1081, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33503305
15.
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Clin Ther
; 31(4): 751-61, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19446148
16.
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.
Clin Rheumatol
; 27(8): 955-60, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18180976
17.
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
Target Oncol
; 17(3): 377, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35412171
18.
Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
Ann Intern Med
; 140(1): 72-3, 2004 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-14706990
19.
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
Bone
; 44(3): 418-22, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18950736
20.
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Curr Med Res Opin
; 24(1): 207-13, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18042311